Advertisement

Latest News

6 in 10 US Women Predicted to Have Cardiovascular Disease by 2050, With Karen Maddox, MD, MPH

52 minutes ago

Maddox discusses the AHA’s recent statement indicating that, should current trends continue, 6 in 10 US women will have cardiovascular disease by 2050.

Clinical Trial Summit 2026: Advanced Therapies, Equity, Global Outlook For Glomerular Diseases

1 hour ago

Experts outline a 2026 vision for glomerular disease care, including new endpoints, combination therapies, and gene therapy advances.

PARASOL, Endpoints, and Rethinking Clinical Trials in Glomerular Disease

1 hour ago

The PARASOL initiative is reshaping glomerular disease trials through shared data and improved surrogate endpoints.

PLA2R, Membranous Nephropathy, and the PARASOL Membranous Project

1 hour ago

PLA2R antibodies are advancing precision care in membranous nephropathy and informing new surrogate endpoints through PARASOL.

Anti-Nephrin Autoantibodies, Precision in Nephrotic Syndrome

1 hour ago

Anti-nephrin autoantibodies are redefining minimal change disease and enabling more precise, steroid-sparing treatment strategies.

Advertisement
Advertisement